Your browser doesn't support javascript.
loading
Platelet-Rich Plasma-Releasate (PRPr) for the Treatment of Discogenic Low Back Pain Patients: Long-Term Follow-Up Survey.
Akeda, Koji; Takegami, Norihiko; Yamada, Junichi; Fujiwara, Tatsuhiko; Ohishi, Kohshi; Tamaru, Satoshi; Sudo, Akihiro.
Afiliação
  • Akeda K; Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.
  • Takegami N; Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.
  • Yamada J; Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.
  • Fujiwara T; Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.
  • Ohishi K; Department of Transfusion Medicine and Cell Therapy, Mie University Hospital, Tsu 514-8507, Japan.
  • Tamaru S; Clinical Research Support Center, Mie University Hospital, Tsu 514-8507, Japan.
  • Sudo A; Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.
Medicina (Kaunas) ; 58(3)2022 Mar 16.
Article em En | MEDLINE | ID: mdl-35334604
ABSTRACT
Background and

Objectives:

Clinical studies of platelet-rich plasma (PRP) for the treatment of low back pain (LBP) have been reported; however, less is known about its long-term efficiency. Materials and

Methods:

This study was a long-term follow-up of a previous prospective clinical feasibility study for the use of PRP releasate (PRPr) to treat discogenic LBP patients. Among 14 patients, 11 patients were evaluated for a long-term survey. The efficacy was assessed by a visual analogue scale (VAS) for LBP intensity and the Roland-Morris Disability Questionnaire (RDQ) for LBP-related disability. Radiographic disc height was evaluated for seven patients.

Results:

Improvements in VAS and RDQ were sustained at an average of 5.9 years after the intradiscal injection of PRPr (p < 0.01 vs. baseline, respectively). Clinically meaningful improvements (more than 30% decrease from baseline) in VAS and RDQ were identified in 91% of patients at final survey. The radiographic measurement of disc height of PRPr-injected discs showed a mild decrease (13.8% decrease compared to baseline) during the average 5.9 years.

Conclusions:

The results of this study with a small number of patients suggest that the intradiscal injection of PRPr has a safe and efficacious effect on LBP improvement for more than 5 years after treatment. Further large-scale studies would be needed to confirm the clinical evidence for the use of PRPr for the treatment of patients with discogenic LBP.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dor Lombar / Plasma Rico em Plaquetas Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Medicina (Kaunas) Assunto da revista: MEDICINA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dor Lombar / Plasma Rico em Plaquetas Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Medicina (Kaunas) Assunto da revista: MEDICINA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão